FR2751226B1 - Formule de vaccin polynucleotidique contre les pathologies du cheval - Google Patents

Formule de vaccin polynucleotidique contre les pathologies du cheval

Info

Publication number
FR2751226B1
FR2751226B1 FR9609400A FR9609400A FR2751226B1 FR 2751226 B1 FR2751226 B1 FR 2751226B1 FR 9609400 A FR9609400 A FR 9609400A FR 9609400 A FR9609400 A FR 9609400A FR 2751226 B1 FR2751226 B1 FR 2751226B1
Authority
FR
France
Prior art keywords
pathologies
polynucleotide vaccine
vaccine formula
formula against
against horse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9609400A
Other languages
English (en)
French (fr)
Other versions
FR2751226A1 (fr
Inventor
Jean Christophe Franc Audonnet
Annabelle Bouchardon
Michel Emile Albert Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Rhone Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux SA filed Critical Rhone Merieux SA
Priority to FR9609400A priority Critical patent/FR2751226B1/fr
Priority to ARP970103113A priority patent/AR009947A1/es
Priority to CZ0017499A priority patent/CZ300593B6/cs
Priority to DE69734778T priority patent/DE69734778T2/de
Priority to NZ333754A priority patent/NZ333754A/en
Priority to CZ20080390A priority patent/CZ301365B6/cs
Priority to AU37727/97A priority patent/AU735372B2/en
Priority to EP05025200A priority patent/EP1647281A3/fr
Priority to PL97331202A priority patent/PL188409B1/pl
Priority to JP09532943A priority patent/JP2000516199A/ja
Priority to EP97934569A priority patent/EP0936922B1/fr
Priority to CA2660355A priority patent/CA2660355C/en
Priority to BR9710502A priority patent/BR9710502A/pt
Priority to PCT/FR1997/001314 priority patent/WO1998003198A1/fr
Priority to CA2260858A priority patent/CA2260858C/en
Publication of FR2751226A1 publication Critical patent/FR2751226A1/fr
Application granted granted Critical
Publication of FR2751226B1 publication Critical patent/FR2751226B1/fr
Priority to US09/232,478 priority patent/US6207166B1/en
Priority to US09/785,055 priority patent/US6558674B1/en
Priority to ARP070101015A priority patent/AR059828A2/es
Priority to JP2007316669A priority patent/JP2008143900A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR9609400A 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies du cheval Expired - Lifetime FR2751226B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR9609400A FR2751226B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies du cheval
ARP970103113A AR009947A1 (es) 1996-07-19 1997-07-11 COMPOSICIoN DE VACUNA PARA EQUIDOS QUE COMPRENDEN TAMBIEN UN VEHíCULO DE VACUNACIoN.
PCT/FR1997/001314 WO1998003198A1 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucleotidique contre les pathologies du cheval
NZ333754A NZ333754A (en) 1996-07-19 1997-07-15 Polynucleotide vaccine formula for treating horse diseases containing a gB and gD gene from EHV
CZ20080390A CZ301365B6 (cs) 1996-07-19 1997-07-15 Imunogenní kompozice pro vyvolání u savce celedi konovitých imunologické odezvy proti viru rinopneumonitidy, použití této kompozice pro výrobu léciva a souprava obsahující tuto kompozici
AU37727/97A AU735372B2 (en) 1996-07-19 1997-07-15 Polynucleotide vaccine formulation against pathologies of the horse
EP05025200A EP1647281A3 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucléotidique contre les pathologies du cheval
PL97331202A PL188409B1 (pl) 1996-07-19 1997-07-15 Szczepionki do leczenia koni, zastosowanie plazmidu do wytwarzania szczepionki i zestaw do szczepienia koni
JP09532943A JP2000516199A (ja) 1996-07-19 1997-07-15 ウマの予防用ポリヌクレオチドワクチン製剤
EP97934569A EP0936922B1 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucleotidique contre les pathologies du cheval
CZ0017499A CZ300593B6 (cs) 1996-07-19 1997-07-15 Vakcína proti viru chripky savcu celedi konovitých EIV, použití této vakcíny a souprava tuto vakcínu obsahující
BR9710502A BR9710502A (pt) 1996-07-19 1997-07-15 FÄrmula de vacina polinucleot¡dica contra as patologias do cavalo
DE69734778T DE69734778T2 (de) 1996-07-19 1997-07-15 Polynukleotid-impfstoffformulierung gegen pferdekrankheiten
CA2260858A CA2260858C (en) 1996-07-19 1997-07-15 Polynucleotide vaccine formulation against pathologies of the horse
CA2660355A CA2660355C (en) 1996-07-19 1997-07-15 Polynucleotide vaccine formulation against pathologies of the horse
US09/232,478 US6207166B1 (en) 1996-07-19 1999-01-15 Polynucleotide formulation against pathologies of the horse
US09/785,055 US6558674B1 (en) 1996-07-19 2001-02-16 Polynucleotide vaccine formulation against pathologies of the horse
ARP070101015A AR059828A2 (es) 1996-07-19 2007-03-12 Formula de vacuna para equidos, su utilizacion y kit de vacunacion
JP2007316669A JP2008143900A (ja) 1996-07-19 2007-12-07 ウマの予防用ポリヌクレオチドワクチン製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609400A FR2751226B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies du cheval

Publications (2)

Publication Number Publication Date
FR2751226A1 FR2751226A1 (fr) 1998-01-23
FR2751226B1 true FR2751226B1 (fr) 1998-11-27

Family

ID=9494494

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9609400A Expired - Lifetime FR2751226B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies du cheval

Country Status (13)

Country Link
US (2) US6207166B1 (enExample)
EP (2) EP1647281A3 (enExample)
JP (2) JP2000516199A (enExample)
AR (2) AR009947A1 (enExample)
AU (1) AU735372B2 (enExample)
BR (1) BR9710502A (enExample)
CA (2) CA2660355C (enExample)
CZ (2) CZ301365B6 (enExample)
DE (1) DE69734778T2 (enExample)
FR (1) FR2751226B1 (enExample)
NZ (1) NZ333754A (enExample)
PL (1) PL188409B1 (enExample)
WO (1) WO1998003198A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
BR0011732B1 (pt) * 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ES2343270T3 (es) 2005-04-25 2010-07-27 Merial Ltd. Vacunas contra el virus nipah.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
EP3213766A1 (en) 2009-12-28 2017-09-06 Merial Ltd. Recombinant ndv antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2011112945A2 (en) 2010-03-12 2011-09-15 Merial Limited Foot and mouth disease virus recombinant vaccines and uses thereof
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
NZ618125A (en) 2011-05-27 2016-03-31 Merial Ltd Genetic vaccines against hendra virus and nipah virus
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EA032389B1 (ru) 2012-02-14 2019-05-31 Мериал, Инк. Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства
HUE033858T2 (en) 2012-02-14 2018-01-29 Merial Inc Rotavirus unit vaccines and method for their preparation and use
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
KR101490292B1 (ko) 2012-04-16 2015-02-04 한국생명공학연구원 신규한 ｈ3ｎ8 말 인플루엔자 바이러스
NZ703297A (en) 2012-06-13 2016-04-29 Merial Ltd Reassortant btv and ahsv vaccines
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
US10010605B2 (en) 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12017502380B1 (en) 2015-06-23 2022-10-26 Merial Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
PH12018500372B1 (en) 2015-08-20 2023-03-15 Merial Inc Fcv recombinant vaccines and uses thereof
AR106026A1 (es) 2015-09-29 2017-12-06 Merial Inc Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
JP6797206B2 (ja) 2015-11-23 2020-12-09 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN109136264B (zh) * 2018-09-19 2022-07-29 天康制药(苏州)有限公司 马疱疹病毒1型gB-gD融合蛋白、重组载体和真核细胞株及其制备方法和疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
SU1671688A1 (ru) * 1989-01-27 1991-08-23 Всесоюзный Научно-Исследовательский Институт Молекулярной Биологии Штамм гибридных культивируемых клеток животных MUS мUSсULUS L. - продуцент моноклональных антител к гликопротеиду Е1 вируса восточного энцефаломиелита лошадей
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
FR2659349B1 (fr) * 1990-03-12 1993-12-24 Rhone Merieux Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus.
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5243121A (en) 1992-03-19 1993-09-07 Engelhard Corporation Fluid catalytic cracking process for increased formation of isobutylene and isoamylenes
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US6565853B1 (en) * 1998-03-27 2003-05-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Recombinant virus

Also Published As

Publication number Publication date
PL331202A1 (en) 1999-07-05
WO1998003198A1 (fr) 1998-01-29
CA2260858A1 (en) 1998-01-29
CZ301365B6 (cs) 2010-01-27
DE69734778T2 (de) 2006-09-07
EP0936922B1 (fr) 2005-11-30
JP2000516199A (ja) 2000-12-05
AU3772797A (en) 1998-02-10
PL188409B1 (pl) 2005-01-31
NZ333754A (en) 2001-03-30
JP2008143900A (ja) 2008-06-26
CZ300593B6 (cs) 2009-06-24
BR9710502A (pt) 1999-08-17
DE69734778D1 (de) 2006-01-05
CA2660355C (en) 2012-05-22
EP1647281A2 (fr) 2006-04-19
AU735372B2 (en) 2001-07-05
EP0936922A1 (fr) 1999-08-25
US6207166B1 (en) 2001-03-27
FR2751226A1 (fr) 1998-01-23
US6558674B1 (en) 2003-05-06
CA2260858C (en) 2011-01-18
AR009947A1 (es) 2000-05-17
CZ17499A3 (cs) 1999-05-12
CA2660355A1 (en) 1998-01-29
EP1647281A3 (fr) 2009-08-05
AR059828A2 (es) 2008-04-30

Similar Documents

Publication Publication Date Title
FR2751223B1 (fr) Formule de vaccin polynucleotidique felin
FR2751225B1 (fr) Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
BR9710502A (pt) FÄrmula de vacina polinucleot¡dica contra as patologias do cavalo
FR2751227B1 (fr) Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
PT1210113E (pt) Composicoes de vacinas de combinacao
DE60021679D1 (de) Endoskop
DE59908145D1 (de) Endoskop
DE60020343D1 (de) Cilostazol enthaltende zubereitung
NO20014323D0 (no) Vaksine
DK1031346T3 (da) Ikke-invasiv vaccination gennem huden
BR0012303B1 (pt) composição de gordura
DZ3219A1 (fr) Vaccin
DE69930258D1 (de) Medizinischer Konnektor
DE60002650D1 (de) Öladjuvierter Impfstoff
HUP0005010A3 (en) Salmonella vaccine
PT1176982E (pt) Solucao oral de prucaloprida
NO20022290D0 (no) Aryloksypropanolaminer for forbedring av husdyravl
FI4299U1 (fi) Saunasuodatin
DE10081188D2 (de) Melken
GB0109332D0 (en) Treatment of young poultry
FR2799889B1 (fr) Connecteur demontable
GB9926055D0 (en) Single use teat
PL331669A1 (en) Multiple-function solution adjuvant for crop protection products
EE9400227A (et) Loomade trihhofüütia vastane vaktsiin

Legal Events

Date Code Title Description
CD Change of name or company name
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 20